Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
IRWD
vs
S&P 500
IRWD
S&P 500
Over the past 12 months, IRWD has significantly outperformed S&P 500, delivering a return of +105% compared to S&P 500's +16% growth.
Stocks Performance
IRWD vs S&P 500
Performance Gap
IRWD vs S&P 500
Performance By Year
IRWD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ironwood Pharmaceuticals Inc
Glance View
Ironwood Pharmaceuticals is a biopharmaceutical company focused on medicines for gastrointestinal, or digestive, disorders. Its main product is Linzess, a prescription drug used for conditions such as irritable bowel syndrome with constipation and chronic idiopathic constipation. The company also works on other gut-related drug programs, but its business is still centered on treating chronic digestive diseases. Ironwood makes money mainly by selling Linzess in the United States and by receiving payments tied to its partnerships outside the U.S. Its customers are not patients directly; the drug is prescribed by doctors and dispensed through pharmacies, with wholesalers and pharmacy benefit managers playing a big role in getting it to patients. What makes Ironwood different is how focused it is. Instead of running a broad drug portfolio, it relies on one core branded medicine and a small set of follow-on programs in the same disease area. That gives it a clear role in the healthcare value chain: it develops gut-focused drugs, commercializes them through partners and the U.S. prescription system, and earns revenue from sales plus collaboration income.